• Optimi Health established wholly owned Optimi Australia to expand distribution and business development in its first commercial market.
• The subsidiary will sell psilocybin and MDMA capsules to clinics and pharmacies under Australia's Authorised Prescriber Scheme.
• Adrian Jones was appointed director of Australian operations, bringing more than 15 years of experience at Bristol Myers Squibb.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optimi Health Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006808), on October 26, 2026, and is solely responsible for the information contained therein.